AMN107

( DrugBank: - / KEGG DRUG: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
34	Neurofibromatosis	2

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	4

34. Neurofibromatosis

Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-003005-10-DK (EUCTR)	06/06/2013	08/05/2013	LOW-GRADE GLIOMA	PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG AD ...	Children, adolescents and young adults with refractory or recurrent low-grade gliomas, and children, ...	Product Name: Nilotinib Product Code: AMN107 Other descriptive name: NILOTINIB HYDROCHLORIDE MONOHYDRA ...	Gustave Roussy	NULL	Not Recruiting			Female: yes Male: yes	160	Phase 2	France;Spain;Denmark;Netherlands;Switzerland
2	NCT01275586 (ClinicalTrials.gov)	January 2011	11/1/2011	Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibroma ...	Pilot Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurof ...	Neurofibromatosis;NF1;Neurofibromas	Drug: Tasigna	Indiana University	Novartis	Completed	18 Years	N/A	All	6	Early Phase 1	United States

First Previous1Next Last

86. Pulmonary arterial hypertension

Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

trials per page:

Showing 1 to 4 of 4 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-019883-36-DE (EUCTR)	13/10/2011	13/05/2011	A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability ...	A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability ...	Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at leas ...	Trade Name: Tasigna® 150 mg Product Name: Tasigna Product Code: AMN107 INN or Proposed INN: nilotinib Pr ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	55		United States;Hungary;Canada;Singapore;Germany;Switzerland;Italy;Korea, Republic of
2	EUCTR2010-019883-36-IT (EUCTR)	20/09/2010	24/09/2010	ND	A 24 week, randomized, double blind, multicenter, placebocontrolled efficacy, safety, tolerability a ...	Pulmonary Arterial Hypertension (PAH) MedDRA version: 14.1;Level: PT;Classification code 10037400;Te ...	Trade Name: TASIGNA INN or Proposed INN: nilotinib Trade Name: TASIGNA INN or Proposed INN: nilotinib Tr ...	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	55		United States;Hungary;Canada;Singapore;Germany;Italy;Korea, Republic of
3	EUCTR2010-019883-36-HU (EUCTR)	31/08/2010	08/07/2010	A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability ...	A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability ...	Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at leas ...	Trade Name: Tasigna® Product Name: Tasigna Product Code: AMN107 INN or Proposed INN: nilotinib Product N ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	66		Hungary;Germany
4	NCT01179737 (ClinicalTrials.gov)	July 2010	3/8/2010	Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial ...	A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability a ...	Pulmonary Arterial Hypertension	Drug: Nilotinib;Drug: Placebo to nilotinib	Novartis Pharmaceuticals	NULL	Terminated	18 Years	N/A	All	23	Phase 2	United States;Canada;Germany;Korea, Republic of;Singapore;Switzerland;Hungary;Italy

First Previous1Next Last